We also provide compelling evidence that the transcription factor SNAI2, in conjunction with MEK1/2 signaling, drives the hybrid EMT phenotype in TPM cancers, facilitating survival and apoptosis resistance through epigenetic suppression of apoptotic markers like BIM and BMF. This evidence concerns the gene BCL2L11 and cancer.